In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections

Rinzo Soejima, Masaru Sumi, Niro Okimoto, Chikara Nakahama, Masakichi Motomiya, Akira Watanabe, Tsukasa Yoshida, Kenichi Takeuchi, Toshiharu Ito, Kosaku Nagai, Hiroyuki Kobayashi, Hiroshi Oshitani, Shigeki Odagiri, Kaneo Suzuki, Yasutsugu Amano, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yukio Matsumoto, Yuji SugimotoHidemi Teramoto, Tatsuya Konishi, Toru Hikita, Michio Yamakido, Kenji Hasegawa, Naoki Yamaoka, Naomi Kodomari, Naoshi Saeki, Kazuaki Goriki, Kenichiro Sadamoto, Toyofumi Mitsuyama, Kohei Hara, Shigeru Kouno, Hironobu Koga, Mitsuo Kaku, Kazuhiro Okuno, Kenji Kawano, Masao Nakatomi, Noriyo Fujita, Akira Yasuoka, Masaru Nasu, Hideaki Shigeno, Yoichiro Goto, Tohru Yamasaki, Hiroyuki Nagai, Kenshi Sato, Jun Goto, Mitsunobu Akashi, Yoritsugu Harada, Saburo Uragami, Hiroshi Nagaoka, Kaoru Nakama, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Masaru Morine, Masanori Uezu

Research output: Contribution to journalArticlepeer-review

Abstract

We carried out bacteriological and clinical studies on intramuscular imipenem/cilastatin sodium (IPM/CS) developed as a new route of administration and obtained the following results. 1. Antimicrobial activity The In vitro antimicrobial activity of imipenem (IPM) against 330 clinical isolates of 11 species was determined and compared with that of piperacillin (PIPC), cefazolin (CEZ), cefotiam (CTM), aztreonam (AZT), sulbactam/cefoperazone (SBT/CPZ), ceftazidime (CAZ), minocycline (MING) and amikacin (AMK). The M IC90 of IPM was 8 µg/ml against Pseudomonas aeruginosa and 1 µg/ml or less against the other organisms, except for methicillin-resistant Staphylococcus aureus (MRSA), whose MIC90 was 128 µg/ml. 2. Clinical efficacy and safety 0.25 g/0.25 g or 0.5 g/0.5 g of intramuscular IPM/CS was administered twice a day for 2–16 days to 62 patients with respiratory tract infections, and clinical efficacy and safety were evaluated. Clinical efficacy in 60 evaluable patients was excellent in 12 patients, good in 33, fair in 10 and poor in 5, with an efficacy rating of 75.0%. The bacteriological eradication rate was 79.3%. Of the 61 patients evaluable for safety, gastrointestinal symptoms such as diarrhea were observed in 3 patients, and inflammation at the injection site and aggravation of pain/numbness in the lower extremities each occurred in one patient, resulting in a total of 5'patients with adverse experiences (8.2%). These improved after discontinuation or completion of the treatment. Abnormal laboratory findings such as abnormalities in liver function tests were observed in 13 patients; however, these findings were mild and transient.

Original languageEnglish
Pages (from-to)60-74
Number of pages15
JournalChemotherapy
Volume40
Issue number1
DOIs
Publication statusPublished - 1992 Jan

Keywords

  • IPM/CS
  • MIC
  • imipenem/cilastatin sodium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections'. Together they form a unique fingerprint.

Cite this